Home/Pipeline/DSP-1181 (pimavanserin)

DSP-1181 (pimavanserin)

Alzheimer's Disease Psychosis

Phase 3ActiveNCT04464551

Key Facts

Indication
Alzheimer's Disease Psychosis
Phase
Phase 3
Status
Active
Company

About Sumitomo Pharma

Sumitomo Pharma is a research-driven pharmaceutical company with a mission to deliver innovative therapeutic solutions for serious unmet medical needs. Its strategic direction is built on a foundation of internal R&D and strategic acquisitions, such as the merger with Myovant Sciences and the acquisition of Tolero Pharmaceuticals, to bolster its pipeline in key therapeutic areas. The company faces challenges from patent expirations but is actively investing in next-generation modalities like cell and gene therapies to drive future growth.

View full company profile

Other Alzheimer's Disease Psychosis Drugs

DrugCompanyPhase
OPC-64005Otsuka HoldingsPhase 3